LifeMD, Inc. (NASDAQ:LFMD) Insider Sells $1,052,300.00 in Stock

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) insider Stefan Galluppi sold 85,000 shares of the company's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $12.38, for a total value of $1,052,300.00. Following the completion of the transaction, the insider now owns 80,449 shares of the company's stock, valued at $995,958.62. The trade was a 51.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

LifeMD Stock Performance

LifeMD stock traded down $0.22 during trading hours on Friday, hitting $14.85. 1,515,497 shares of the stock were exchanged, compared to its average volume of 1,048,596. LifeMD, Inc. has a 12 month low of $3.99 and a 12 month high of $15.46. The business's 50-day moving average is $9.58 and its two-hundred day moving average is $6.95. The stock has a market capitalization of $674.71 million, a P/E ratio of -43.69 and a beta of 2.42.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.05. The business had revenue of $65.70 million for the quarter, compared to the consensus estimate of $62.47 million. On average, equities analysts predict that LifeMD, Inc. will post -0.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. B. Riley raised shares of LifeMD to a "strong-buy" rating in a report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and set a $14.00 price target on shares of LifeMD in a research note on Wednesday, April 30th. BTIG Research lifted their price objective on LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $15.00 target price on shares of LifeMD in a report on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $12.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC acquired a new stake in LifeMD in the 1st quarter valued at about $35,000. CWM LLC increased its holdings in shares of LifeMD by 17.5% in the first quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after purchasing an additional 1,351 shares in the last quarter. ProShare Advisors LLC acquired a new stake in shares of LifeMD in the fourth quarter valued at approximately $51,000. Balyasny Asset Management L.P. bought a new position in LifeMD in the 4th quarter worth approximately $52,000. Finally, Oxford Asset Management LLP acquired a new position in LifeMD during the 4th quarter worth $52,000. Institutional investors and hedge funds own 35.52% of the company's stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.